Search
Globally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries.
The Rio Tinto Children's Diabetes Centre is a research centre that aims to improve the lives of children and young adults living with diabetes by bringing together research, education and clinical care.
The Centre includes researchers at The Kids Research Institute Australia’s Diabetes Research Team and the Diabetes Service at the Perth Children’s Hospital.
Type 1 diabetes is a chronic autoimmune disease that results from the immune system attacking the insulin-producing cells of the pancreas. Unlike type 2 diabetes which is potentially preventable, type 1 is a non-preventable disease - currently, its exact cause is not known and there is no cure.
Many of the Centre's researchers have been responsible for discovering and contributing to real game-changers, making a difference to children with diabetes.
We are trying to understand what underlies mental health problems in young people with diabetes, with a school-related focus, and how we can best treat them.
Our research focuses on what are the best ways for patients with type 1 diabetes to exercise safely.
Much of our research focuses on the safety and the use of emerging technologies for insulin pumps and other diabetes treatment technology.
Read about the Research Focus Area Leads at the Children's Diabetes Centre.